DK

Detlef Kozian

SA Sanofi-Aventis: 8 patents #170 of 1,008Top 20%
SA Sanofi: 4 patents #416 of 1,881Top 25%
SA Sanofi-Aventis: 4 patents #111 of 563Top 20%
AG Aventis Pharma Deutschland Gmbh: 3 patents #103 of 418Top 25%
📍 Frankfurt am Main, DE: #128 of 1,925 inventorsTop 7%
Overall (All Time): #239,473 of 4,157,543Top 6%
19
Patents All Time

Issued Patents All Time

Showing 1–19 of 19 patents

Patent #TitleCo-InventorsDate
9346757 Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation Marc Nazare, Andreas Evers, Werngard Czechtizky 2016-05-24
9346762 Pyrazole derivatives and their use as LPAR5 antagonists Marc Nazare, Andreas Evers, Werngard Czechtizky 2016-05-24
9221784 Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists Marc Nazare, Martin Bossart, Werngard Czechtizky, Andreas Evers 2015-12-29
8420321 Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism Stefan Schaefer, Bernward Schoelkens, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard +1 more 2013-04-16
8329167 EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases Matthias Herrmann 2012-12-11
8211427 EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases Matthias Herrmann 2012-07-03
8198022 Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Evi Kostenis, Karl-Ernst Siegler, Martina Jacobs, Sylvain Ricard, Sandrine Mace +1 more 2012-06-12
8114398 EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease Matthias Herrmann 2012-02-14
8084198 Use of a GIP promoter polymorphism Matthias Herrmann, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace 2011-12-27
8071297 Method for the diagnosis and treatment of cardiovascular diseases Matthias Herrmann, Thomas Leeuw, Wilfried Renner, Winfried Maerz 2011-12-06
7985562 Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism Stefan Schaefer, Bernward Schoelkens, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard +1 more 2011-07-26
7892744 Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders Joerg Czech, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace 2011-02-22
7888020 Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Evi Kostenis, Karl-Ernst Siegler, Martina Jacobs, Sylvain Ricard, Sandrine Mace +1 more 2011-02-15
7785781 Method of diagnosis of a predisposition to develop thrombotic disease and its uses Matthias Herrmann, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace 2010-08-31
7560290 Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism Stefan Schaefer, Bernward Schoelkens, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard +1 more 2009-07-14
7262273 Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Evi Kostenis, Karl-Ernst Siegler, Martina Jacobs, Jean-Francois Deleuze, Sylvain Ricard +1 more 2007-08-28
6645741 Two-color differential display as a method for detecting regulated genes Birgit Reuner 2003-11-11
6602699 Promotor for functional characterization of G-protein coupled receptors in the yeast saccharomyces cerevisiae Almut Nitsche, Pauline Fraissignes, Sabine Gratzer, Ekkehard Leberer 2003-08-05
6342376 Two-color differential display as a method for detecting regulated genes Birgit Reuner 2002-01-29